GHDX

Genomic Health, Inc. Press Releases

$27.49
*  
0.11
0.4%
Get GHDX Alerts
*Delayed - data as of Jul. 23, 2014  -  Find a broker to begin trading GHDX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Invitae Offers Multi-Gene Testing for Hereditary Pancreatic Cancer, Providing Clinicians with a Reliable, Fast, Affordable Option for Patients
6/12/2014 8:30:00 AM - Business Wire

Genomic Health Announces Positive Topline Results of Second Large, Independent Validation Study of Oncotype DX® in DCIS Breast Cancer
6/11/2014 8:00:00 AM - PR Newswire

Multiple studies presented at 2014 ASCO® annual meeting reinforce unique, practice-changing value of Oncotype DX® breast cancer test
6/10/2014 3:00:00 AM - Business Wire

Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers
6/3/2014 8:00:00 AM - PR Newswire

Multiple Studies Presented at ASCO® Annual Meeting Demonstrate Unique, Practice-Changing Impact of Oncotype DX® to Optimize Cancer Care
6/1/2014 9:00:00 AM - PR Newswire

Oncotype DX® Breast Cancer Test Predicts Late Recurrence Five to 15 Years Out
5/29/2014 8:00:00 AM - PR Newswire

Genomic Health to Present at Two Upcoming Investor Conferences
5/23/2014 8:00:00 AM - PR Newswire

Genomic Health Announces Data Reinforcing Robustness of Oncotype DX® Prostate Cancer Test at 2014 American Urological Association (AUA) Annual Meeting
5/20/2014 4:57:00 PM - PR Newswire

European Urology Published Groundbreaking Results from Three Studies Demonstrating Genomic Health's Oncotype DX® Test Predicts Prostate Cancer Aggressiveness at Diagnosis
5/16/2014 4:00:00 PM - PR Newswire

Genomic Health's Oncotype DX® Becomes First Multi-Gene Test for Cancer Management To Be Included in National Institutes of Health's (NIH) Genetic Testing Registry
5/14/2014 8:00:00 AM - PR Newswire

Genomic Health Announces First Quarter 2014 Financial Results and Business Progress
5/6/2014 4:02:00 PM - PR Newswire

Genomic Health Announces Presentation of Multiple Oncotype DX® Studies in Breast, Prostate, Colon and Renal Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/5/2014 8:00:00 AM - PR Newswire

Oncotype DX® Changes Treatment Decisions in 45 Percent of Stage II Colon Cancer Patients
5/2/2014 8:00:00 AM - PR Newswire

Genomic Health to Announce First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 6, 2014
4/29/2014 8:00:00 AM - PR Newswire